Opaleye Management
Latest statistics and disclosures from Opaleye Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are OCUL, HROW, TGTX, KROS, RYTM, and represent 44.34% of Opaleye Management's stock portfolio.
- Added to shares of these 10 stocks: JSPR (+$13M), LYEL (+$7.5M), CMPX (+$6.3M), OCUL (+$5.3M), NTLA, SVRA, RVNC, ZNTL, ALLK, IBIO.
- Started 13 new stock positions in LYEL, RGLS, CMPX, DSGN, RPTX, GKOS, ZNTL, SVRA, PMVP, JSPR. IBIO, ALLK, RVNC.
- Reduced shares in these 10 stocks: SLRN (-$17M), IDYA (-$11M), BHVN (-$8.6M), ARQT (-$6.3M), MRNS (-$6.1M), RYTM, CPRX, LRMR, Jasper Therapeutics, KALV.
- Sold out of its positions in ARQT, IDYA, Jasper Therapeutics, KALV, MRNS, STRO, BHVN, KNSA.
- Opaleye Management was a net seller of stock by $-4.0M.
- Opaleye Management has $437M in assets under management (AUM), dropping by 17.02%.
- Central Index Key (CIK): 0001595855
Tip: Access up to 7 years of quarterly data
Positions held by Opaleye Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Opaleye Management
Opaleye Management holds 51 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Ocular Therapeutix (OCUL) | 13.9 | $61M | +9% | 6.7M | 9.10 |
|
| Harrow Health (HROW) | 11.9 | $52M | +2% | 3.9M | 13.23 |
|
| Tg Therapeutics (TGTX) | 7.9 | $35M | +2% | 2.3M | 15.21 |
|
| Keros Therapeutics (KROS) | 5.6 | $24M | +2% | 368k | 66.20 |
|
| Rhythm Pharmaceuticals (RYTM) | 5.1 | $22M | -15% | 515k | 43.33 |
|
| Catalyst Pharmaceutical Partners (CPRX) | 3.7 | $16M | -20% | 1.0M | 15.94 |
|
| Arvinas Ord (ARVN) | 3.1 | $14M | +25% | 330k | 41.28 |
|
| Iovance Biotherapeutics (IOVA) | 3.0 | $13M | 897k | 14.82 |
|
|
| Jasper Therapeutics Com New (JSPR) | 2.9 | $13M | NEW | 436k | 29.36 |
|
| Edgewise Therapeutics (EWTX) | 2.8 | $12M | -4% | 665k | 18.24 |
|
| 4d Molecular Therapeutics In (FDMT) | 2.5 | $11M | +11% | 344k | 31.86 |
|
| Codexis (CDXS) | 2.5 | $11M | +2% | 3.1M | 3.49 |
|
| Protara Therapeutics Com Stk (TARA) | 2.5 | $11M | 2.7M | 4.01 |
|
|
| Acelyrin (SLRN) | 2.4 | $11M | -61% | 1.6M | 6.75 |
|
| Eton Pharmaceuticals (ETON) | 2.1 | $9.2M | -3% | 2.4M | 3.75 |
|
| Trevi Therapeutics (TRVI) | 2.1 | $9.1M | +4% | 2.6M | 3.45 |
|
| Lyell Immunopharma (LYEL) | 1.7 | $7.5M | NEW | 3.4M | 2.23 |
|
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.7 | $7.5M | +18% | 315k | 23.65 |
|
| Ventyx Biosciences (VTYX) | 1.6 | $7.1M | +12% | 1.3M | 5.50 |
|
| Intellia Therapeutics (NTLA) | 1.6 | $7.0M | +157% | 255k | 27.51 |
|
| Compass Therapeutics (CMPX) | 1.4 | $6.3M | NEW | 3.2M | 1.98 |
|
| Xoma Corp Del Com New (XOMA) | 1.4 | $6.0M | 250k | 24.05 |
|
|
| Liquidia Corporation Com New (LQDA) | 1.3 | $5.8M | -11% | 395k | 14.75 |
|
| Vaxcyte (PCVX) | 1.3 | $5.8M | -5% | 85k | 68.31 |
|
| Nyxoah S A SHS (NYXH) | 1.0 | $4.3M | -7% | 320k | 13.49 |
|
| Savara (SVRA) | 1.0 | $4.3M | NEW | 855k | 4.98 |
|
| Syros Pharmaceuticals Com New (SYRS) | 1.0 | $4.2M | +119% | 788k | 5.35 |
|
| Urogen Pharma (URGN) | 0.9 | $4.1M | -15% | 270k | 15.00 |
|
| Revance Therapeutics (RVNC) | 0.9 | $3.9M | NEW | 785k | 4.92 |
|
| Applied Therapeutics (APLT) | 0.8 | $3.7M | +62% | 1.8M | 2.07 |
|
| Relmada Therapeutics (RLMD) | 0.8 | $3.5M | -13% | 759k | 4.65 |
|
| Protagonist Therapeutics (PTGX) | 0.7 | $3.3M | 113k | 28.93 |
|
|
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.7 | $3.2M | 8.0M | 0.40 |
|
|
| Zentalis Pharmaceuticals (ZNTL) | 0.7 | $3.2M | NEW | 200k | 15.76 |
|
| Allakos (ALLK) | 0.7 | $3.1M | NEW | 2.4M | 1.26 |
|
| Gossamer Bio (GOSS) | 0.7 | $2.9M | -18% | 2.4M | 1.18 |
|
| Ibio Com New (IBIO) | 0.6 | $2.8M | NEW | 680k | 4.06 |
|
| Verastem Com New (VSTM) | 0.6 | $2.5M | 211k | 11.80 |
|
|
| Aligos Therapeutics (ALGS) | 0.4 | $1.6M | +25% | 1.6M | 0.98 |
|
| Context Therapeutics (CNTX) | 0.4 | $1.5M | +13% | 1.1M | 1.38 |
|
| Precigen (PGEN) | 0.3 | $1.4M | -6% | 948k | 1.45 |
|
| Larimar Therapeutics (LRMR) | 0.3 | $1.3M | -72% | 174k | 7.59 |
|
| Fulcrum Therapeutics (FULC) | 0.3 | $1.2M | 130k | 9.44 |
|
|
| Morphosys Sponsored Ads (MOR) | 0.3 | $1.2M | -55% | 65k | 18.14 |
|
| Glaukos (GKOS) | 0.2 | $809k | NEW | 8.6k | 94.29 |
|
| Pmv Pharmaceuticals (PMVP) | 0.2 | $802k | NEW | 472k | 1.70 |
|
| Biodesix (BDSX) | 0.2 | $765k | +7% | 535k | 1.43 |
|
| Regulus Therapeutics (RGLS) | 0.1 | $491k | NEW | 170k | 2.88 |
|
| Design Therapeutics (DSGN) | 0.1 | $456k | NEW | 113k | 4.03 |
|
| Repare Therapeutics Ord (RPTX) | 0.1 | $318k | NEW | 68k | 4.71 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.0 | $210k | -31% | 210k | 1.00 |
|
Past Filings by Opaleye Management
SEC 13F filings are viewable for Opaleye Management going back to 2013
- Opaleye Management 2024 Q1 filed May 15, 2024
- Opaleye Management 2023 Q4 filed Feb. 14, 2024
- Opaleye Management 2023 Q3 filed Nov. 15, 2023
- Opaleye Management 2023 Q2 filed Aug. 14, 2023
- Opaleye Management 2023 Q1 filed May 15, 2023
- Opaleye Management 2022 Q4 filed Feb. 10, 2023
- Opaleye Management 2022 Q3 filed Nov. 14, 2022
- Opaleye Management 2022 Q2 filed Aug. 15, 2022
- Opaleye Management 2022 Q1 filed May 16, 2022
- Opaleye Management 2021 Q4 filed Feb. 14, 2022
- Opaleye Management 2021 Q3 filed Nov. 16, 2021
- Opaleye Management 2021 Q2 filed Aug. 16, 2021
- Opaleye Management 2021 Q1 filed May 18, 2021
- Opaleye Management 2020 Q4 filed Feb. 12, 2021
- Opaleye Management 2020 Q3 filed Nov. 16, 2020
- Opaleye Management 2020 Q2 filed Aug. 14, 2020